<DOC>
	<DOC>NCT01844661</DOC>
	<brief_summary>The investigators will evaluate the safety of weekly infusions (n=6) of CELYVIR in children and adults with metastatic and refractory solid tumors. CELYVIR consists in bone marrow-derived autologous mesenchymal stem cells (MSCs) infected with ICOVIR5, an oncolytic adenovirus. In addition to data on toxicities the investigators will evaluate clinical response.</brief_summary>
	<brief_title>Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.</brief_title>
	<detailed_description />
	<criteria>Children: Up to 18 yrs. Refractory to at least 2 previous therapy lines. Life expectancy more than 6 months. Measurable disease. Adults: 1875 yrs. Refractory to at least 2 previous therapy lines. ECOG (Eastern Cooperative Oncology Group) &lt;2. Measurable disease. Pregnancy. Central Nervous System metastasis. Experimental therapy during the previous month. Chemotherapy less than 3 weeks previous. Any organ functionally impaired. Concurrent infectious disease.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Mesenchymal stem cells</keyword>
	<keyword>Oncolytic adenovirus</keyword>
</DOC>